Trehalose improved muscle function in a mouse model of HSPB8-related myopathy
Original source
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy-modulating therapy. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
- Peer review
- Preprint, not yet peer reviewed
Population inferred from the title and abstract by Compass.
Related topics
Trehalose improved motor performance and several disease-related measures in mice carrying the HSPB8 c.515dupC mutation. The treatment increased HSPB8 levels and reduced abnormal autophagy and TDP-43 findings in muscle tissue. The study was conducted in a mouse model of HSPB8-associated myopathy, not in people with ALS or myopathy.
Why this matters
The findings support further study of autophagy enhancement in HSPB8-related myopathy. They do not show that trehalose is safe or effective in people, and they do not currently change treatment for ALS/MND or HSPB8-related disease.
Limitations and context
This is a preprint describing laboratory and mouse research, not a peer-reviewed clinical study. The mice developed late-onset weakness and mild myopathy without motor-neuron degeneration, so the model does not reproduce every feature of human disease. Human safety and benefit remain untested, and the report comes from a single study.